



Hepatitis C among people who inject drugs: Human Rights and Access to HCV Therapies

Edo Agustian
 Indonesian Network of People Who Use Drugs
kornas@pkni.org


Background :


- Number of PWID : 105,784 (73,663 – 201,131)
- HIV prevalence among PWID : 36%
- Hep C prevalence among PWID : 77,3%
- The Ministry of Health first established a national program focused on viral hepatitis in 2011, under the Sub Directorate for Gastrointestinal Infections and Diarrheal Diseases.
- Routine National Surveillance for viral hepatitis: **No**
- National guideline for Hep C Care, Support and Treatment : **draft currently in progress**

Source: PKNI (2013) The urgent need for improved hepatitis C prevention, care and treatment for PWID in Indonesia


Monitoring of the quality of harm reduction programs in 9 provinces by the drug user community

PWID Received HIV-AIDS Prevention Information





Indonesia in a global context: treatment cost



Source: Open Society Foundations (2013) "Hepatitis C Treatment: Price, Profits, and Barriers to Access," Available at: <http://www.opensocietyfoundations.org/sites/default/files/hepatitis-c-treatment-20130807.pdf>.

Treatment cost: continued

Hepatitis C Diagnostics and Treatment Costs in Indonesia

Supporting diagnostic tests for Hep C

- Hep C antibody test: US\$ 25 – 30
- Hep C RNA test: US\$ 120
- Hepatitis C genotype test: US\$ 325
- Abdomen ultrasound: US\$ 25 – 30
- Liver function test (LFT): \$7.50
- Liver biopsy: \$60
- Fibroscan: \$85

Total: \$600 - \$650

Treatment cost: continued

Treatment costs

Pegasys® (180 Mcg) + ribavirin:

Per dose: US\$ 300

24-week course: US\$ 7,200

48-week course: US\$ 14,400

Pegintron (100 mcg) + ribavirin

per dose : \$290

Indonesian averages income in 2014: \$ 4000 per year

Beyond treatment costs: continued

- National insurance scheme (JKN) announced on 1 January 2014 by Indonesian Presidential Decree no: 12/2013 covers Hep C treatment

JKN monthly cost for those who are employed: 4-5% of salary

Monthly cost for unemployed: \$2-\$5 per month

According to section 25 (h), “people with drug and/or alcohol dependency” are excluded from National Insurance Scheme

Beyond treatment costs

- Government employee insurance covered Hep C treatment → PWID expected to finance their own treatment.
- Other challenges are: Lack of knowledge about Hep C among general population, health care worker, harm reduction services and PWID (PKNI qualitative study in 2011 in 4 cities).

New therapies

- Sofosbuvir and Simeprevir. More focused on Sofosbuvir as Simeprevir is contraindicated with our best drugs for HIV.
- Gilead- Q2 of 2014 to be registered in Indonesia but not as yet.
- Registration should be fast tracked to enable access.
- One patent already granted on Sofosbuvir.
- The prices in developing markets are too high and unaffordable.
- PWID are excluded from any clinical trials.





For more information and resources, please visit the Indonesian Drug Users' Network's website or write to us directly:

www.pkni.org

kornas@pkni.org

Thank you!

CCB
